AustinPx Wins FDA Advanced Manufacturing Technology Designation for KinetiSol

AustinPx said the FDA’s drug center has granted Advanced Manufacturing Technology designation to KinetiSol, the company’s solvent-free platform for making amorphous solid dispersions of poorly soluble oral drugs. The designation is meant to support earlier regulator engagement and give drug developers more predictability as candidates move from development to commercialization.

Why it matters: - The FDA designation can make it easier for pharma and biotech sponsors to advance poorly soluble oral drug candidates that use KinetiSol. - AustinPx said the recognition should give sponsors earlier FDA engagement, more regulatory clarity and a cleaner path toward commercial manufacturing. - The designation also puts KinetiSol in a category the FDA created to support manufacturing methods that may improve quality, shorten development and strengthen supply reliability.

What happened: - AustinPx announced that the FDA’s Center for Drug Evaluation and Research granted Advanced Manufacturing Technology designation to KinetiSol Technology. - KinetiSol is a solvent-free process for producing amorphous solid dispersions of poorly soluble oral drug candidates. - The technology can be used from early development through commercial manufacturing. - AustinPx said the designation was awarded after a comprehensive FDA review of KinetiSol Technology.

The details: - For sponsors using KinetiSol as the amorphous dispersion manufacturing process, the designation can create opportunities for earlier FDA engagement during development and application review. - AustinPx said the added communication may help sponsors address Chemistry, Manufacturing and Controls questions sooner. - The company said the designation may also reduce regulatory uncertainty and help teams plan more efficiently as programs move toward commercial manufacturing. - The FDA’s AMT Designation Program is designed to encourage early adoption of innovative manufacturing methods. - The program aims to support product quality, reduce drug development time, strengthen supply reliability and help prevent or address drug shortages. - Chris Brough, chief technology officer and co-inventor of KinetiSol, said the company has spent more than 15 years developing the platform and has applied it to more than 70 poorly soluble molecules. - Brough said the FDA recognition reinforces KinetiSol’s value as a commercial manufacturing technology as more clients move late-stage candidates toward commercialization.

Between the lines: - The designation gives AustinPx a regulatory signal that may matter as more sponsors look for manufacturing platforms that work well for difficult molecules and also fit FDA expectations. - For drug developers, the bigger appeal is not just technical performance. It is the chance to lower risk in the most time-consuming parts of development and review.

What's next: - AustinPx said sponsors can use the designation as they continue developing KinetiSol-enabled candidates. - The company directed readers to more information about KinetiSol and the AMT designation. - AustinPx said the platform remains available through its CDMO services for small molecule drugs, including analytical and formulation development and cGMP manufacturing. - The company said KinetiSol will continue to be part of its phase-appropriate development and bioavailability enhancement work for poorly soluble molecules.

The bottom line: - The FDA’s AMT designation gives KinetiSol a formal regulatory boost that could make AustinPx more attractive to sponsors developing hard-to-formulate oral drugs.